BACKGROUND: Treatment goals have been developed to optimize daily clinical practice psoriasis care, but have not yet been studied in real life. OBJECTIVES: To investigate to what extent treatment decisions made by dermatologists in daily clinical practice for patients with psoriasis on biologics are already in accordance with treatment goals without the active application of the treatment goals algorithm. METHODS: Data were extracted from a prospective daily practice cohort of patients with psoriasis on biologics. Analysis was done on effectiveness (Psoriasis Area and Severity Index score) and quality of life (Dermatology Life Quality Index questionnaire). Treatment decisions such as dosage adjustments, combination treatments, or switching therapy were compared with the treatment goals algorithm. RESULTS: In 64% (253 of 395) of visits, physicians followed the treatment goals algorithm. There were 162 (41%) visits in which there should have been a treatment modification according to treatment goals (group Modify) and a modification was indeed made in 59 of these 162 visits (36%). In 233 (59%) visits no treatment modification was necessary (group Continue) and therapy was indeed not modified in 194 of 233 visits (83%). CONCLUSIONS: Physicians acted in accordance with treatment goals in the majority of patient visits. In the patient group not achieving these goals, physicians should have modified therapy according to treatment goals but continued the same therapeutic regimen in the majority of visits. Optimizing therapy and defining barriers in the latter group might increase treatment results in daily practice psoriasis care.
BACKGROUND: Treatment goals have been developed to optimize daily clinical practice psoriasis care, but have not yet been studied in real life. OBJECTIVES: To investigate to what extent treatment decisions made by dermatologists in daily clinical practice for patients with psoriasis on biologics are already in accordance with treatment goals without the active application of the treatment goals algorithm. METHODS: Data were extracted from a prospective daily practice cohort of patients with psoriasis on biologics. Analysis was done on effectiveness (Psoriasis Area and Severity Index score) and quality of life (Dermatology Life Quality Index questionnaire). Treatment decisions such as dosage adjustments, combination treatments, or switching therapy were compared with the treatment goals algorithm. RESULTS: In 64% (253 of 395) of visits, physicians followed the treatment goals algorithm. There were 162 (41%) visits in which there should have been a treatment modification according to treatment goals (group Modify) and a modification was indeed made in 59 of these 162 visits (36%). In 233 (59%) visits no treatment modification was necessary (group Continue) and therapy was indeed not modified in 194 of 233 visits (83%). CONCLUSIONS: Physicians acted in accordance with treatment goals in the majority of patient visits. In the patient group not achieving these goals, physicians should have modified therapy according to treatment goals but continued the same therapeutic regimen in the majority of visits. Optimizing therapy and defining barriers in the latter group might increase treatment results in daily practice psoriasis care.
Authors: N H Shear; M Hartmann; M E Toledo-Bahena; M Gilbert; A Katsambas; R Yao; Z Popmihajlov Journal: Qual Life Res Date: 2016-02-11 Impact factor: 4.147
Authors: Marloes E van Muijen; Tamara W van Hal; Hans M M Groenewoud; Juul M P A van den Reek; Elke M G J de Jong Journal: Psoriasis (Auckl) Date: 2020-10-05
Authors: Marloes E van Muijen; S Atalay; L J van Vugt; L M D Vandermaesen; J M P A van den Reek; E M G J de Jong Journal: Drugs Real World Outcomes Date: 2021-03-28
Authors: Sang Woong Youn; Bo Ri Kim; Joo Heung Lee; Hae Jun Song; Yong Beom Choe; Ji Ho Choi; Nack In Kim; Kwang Joong Kim; Jai Il Youn Journal: Ann Dermatol Date: 2015-03-24 Impact factor: 1.444
Authors: Y Okubo; D Tsuruta; A C Tang; S Inoue; H Torisu-Itakura; T Hanada; M Ohtsuki Journal: J Eur Acad Dermatol Venereol Date: 2017-11-06 Impact factor: 6.166